Ascendis Pharma (ASND) Reports Positive Top-Line Results from Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency, Demonstrating Superiority on Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to Ascendis Pharma (ASND) Reports Positive Top-Line Results from Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency, Demonstrating Superiority on Primary Endpoint

Ascendis Pharma (ASND) Prices 4.166M ADS Offering at $120/ADS

March 6, 2019 5:57 AM EST

Ascendis Pharma A/S (NASDAQ: ASND) today announced the pricing of its underwritten public offering of 4,166,667 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of $120.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close... More

Ascendis Pharma (ASND) PT Raised to $185 at Cantor Fitzgerald

March 4, 2019 10:33 AM EST

Cantor Fitzgerald analyst Alethia Young raised the price target on Ascendis Pharma (NASDAQ: ASND) to $185.00 (from $100.00) while maintaining a Overweight rating.

... More

Ascendis Pharma (ASND) received FDA orphan status for its treatment of Achondroplasia

February 28, 2019 12:07 PM EST

Ascendis Pharma (NASDAQ: ASND) received FDA orphan status for its treatment of Achondroplasia.

... More